Literature DB >> 17443735

Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma.

Tristan D Yan1, Julie King, Ardalan Ebrahimi, Adrian Sjarif, Derek Glenn, Karin Steinke, David L Morris.   

Abstract

BACKGROUND: Lung radiofrequency ablation (RFA) is a relatively safe procedure and may have a useful role in the management of non-surgical candidates with colorectal pulmonary metastases.
METHODS: This study consisted of 30 patients, who had previously undergone hepatectomy for colorectal liver metastases and subsequently developed pulmonary metastases, which were then treated with lung RFA. Lung RFA was performed percutaneously under local anesthesia and conscious sedation. The primary aim of this article was to demonstrate the survival outcome in this particular patient population after lung RFA. The secondary aim was to assess the prognostic indicators for survival after lung RFA.
RESULTS: The median survival after lung RFA was 32 months, with 3-year survival rate of 45%. The following four factors were found to significantly influence survival in univariate analysis: size of the largest pulmonary metastasis (P = 0.032), proximity of metastases to major pulmonary vessels (P = 0.003), pre-lung RFA CEA levels (P = 0.013) and post-lung RFA CEA levels (P = 0.022).
CONCLUSIONS: Lung RFA may have a useful role in the management of non-surgical candidates with colorectal pulmonary metastases. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443735     DOI: 10.1002/jso.20810

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  [Laser ablation. Do we still need it?].

Authors:  C Rosenberg; C O M Hoffmann; B Mensel; R Puls; N Hosten
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

Review 2.  Critical questions in the imaging of colorectal hepatic metastases.

Authors:  Dow-Mu Koh; Jonathan Berry
Journal:  Cancer Imaging       Date:  2008-10-04       Impact factor: 3.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.